Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.


Clinical Trial Description

Following 3 loading doses, participants receive chemotherapy and study drug on a 21-day cycle during the Treatment Period (Chemotherapy Period) until disease progression, completion of 6 cycles, toxicity or voluntary participant withdrawal. Participants who do not have documented disease progression and have completed a minimum of four cycles of chemotherapy continue to receive weekly Study Drug maintenance therapy during the Maintenance Period until disease progression or the participant fulfills one of the other reasons for withdrawal from protocol treatment, unless they have been discontinued from protocol treatment for unacceptable toxicity related to study drug. All participants have an End of Treatment (EOT) visit when they are withdrawn from all study treatment (chemotherapy and maintenance). All participants are followed until documented disease progression. Once disease progression is documented, participants enter a Survival Follow-up Period during which data are collected regarding further cancer therapy, secondary malignancy, and survival status. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01454089
Study type Interventional
Source OncoGenex Technologies
Contact
Status Completed
Phase Phase 2
Start date October 2011
Completion date November 2014

See also
  Status Clinical Trial Phase
Completed NCT00151034 - Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer Phase 2
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Completed NCT03219333 - A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Phase 2
Completed NCT04052113 - Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer
Terminated NCT02543645 - A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Phase 1
Active, not recruiting NCT03288545 - A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer Phase 1/Phase 2
Not yet recruiting NCT05025930 - Evaluate the Safety and Effectiveness of the Endoscopic Surgical Instrument Control System (SP1000). N/A
Not yet recruiting NCT05135520 - Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Kidney Specimen N/A
Withdrawn NCT04630483 - Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery
Terminated NCT02386111 - A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03081858 - Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04644432 - Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma Phase 2
Recruiting NCT05308771 - To Investigate the Use of a New Syringe "Visual Pressure Control (VPC)" for Epidural Anesthesia in Children Surgery N/A
Terminated NCT00226954 - Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer Phase 2
Completed NCT05113134 - Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Specimen N/A
Completed NCT04213157 - Laparoscopic Partial Nephrectomy for cT1 Tumors
Completed NCT02780687 - Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy Phase 2
Recruiting NCT04922047 - Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) Phase 1/Phase 2
Not yet recruiting NCT06353906 - Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer Phase 2
Recruiting NCT05935748 - Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) Phase 2